دورية أكاديمية
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
| العنوان: | Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer |
|---|---|
| المؤلفون: | Morgans, Alicia K., Chen, Yu-Hui, Sweeney, Christopher J., Jarrard, David F., Plimack, Elizabeth R., Gartrell, Benjamin A., Carducci, Michael A., Hussain, Maha, Garcia, Jorge A., Cella, David, DiPaola, Robert S., Patrick-Miller, Linda J. |
| المصدر: | Internal Medicine Faculty Publications |
| بيانات النشر: | UKnowledge |
| سنة النشر: | 2018 |
| المجموعة: | University of Kentucky: UKnowledge |
| مصطلحات موضوعية: | docetaxel, androgen deprivation therapy, prostate cancer, metastatic cancer, quality of life, Clinical Trials, Hormones, Hormone Substitutes, and Hormone Antagonists, Medicine and Health Sciences, Oncology, Rehabilitation and Therapy |
| الوصف: | Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostate cancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+D and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months. The Wilcoxon signed rank test was used to examine changes over time. Mixed-effect models compared the QOL between arms at each time point. Results Seven hundred ninety men were randomly assigned (ADT+D [n = 397] and ADT[ n = 393]) and completed FACT-P (90% at baseline, 86% at 3 months, 83% at 6 months, 78% at 9 months, and 77% at 12 months). ADT+D patients reported a statistically significant decline in FACT-P at 3 months (P < .001) but FACT-P did not differ significantly between baseline and 12 months (P = .38). ADT+D FACT-P scores were significantly lower at 3 months (P = .02) but significantly higher at 12 months (P = .04) when compared with ADT FACT-P scores. Differences did not exceed the minimal clinically important difference at any time point. ADT+D patients reported significantly lower Functional Assessment of Chronic Illness Therapy-Fatigue scores at 3 months than did ADT patients (P < .001). Over time, both arms reported significantly poorer FACT-Taxane scores (P < .001) when compared with baseline. Brief Pain Inventory scores were similar between arms. Conclusion Although ADT+D was associated with statistically worse QOL at 3 months, QOL was better at 12 months for ADT+D patients than for ADT patients. Both arms reported a similar minimally changed QOL over time, suggesting that ADT+D is not associated with a ... |
| نوع الوثيقة: | text |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | Clinical trial information: NCT00309985 Listen to the podcast by Dr Alibhai at ascopubs.org/jco/podcasts . Appendix: https://doi.org/10.1200/JCO.2017.75.3335Test Supplements: https://doi.org/10.1200/JCO.2017.75.3335Test Disclosures provided by the authors are available with this article at jco.org .; https://uknowledge.uky.edu/internalmedicine_facpub/138Test; https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1138&context=internalmedicine_facpubTest |
| الإتاحة: | https://doi.org/10.1200/JCO.2017.75.3335Test https://uknowledge.uky.edu/internalmedicine_facpub/138Test https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1138&context=internalmedicine_facpubTest |
| رقم الانضمام: | edsbas.62E44872 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |